In addition, high anti-SELENBP1 levels are also observed in patients with serous ovary cancer, which suggests SELENBP1 participates in an autoimmune process during ovary cancer development (Yu-Rice et al., 2017). Here, SELENBP1 is linked to ovarian cancer.